| Literature DB >> 32338589 |
Rachel Jewkes1, Andrew Gibbs1, Esnat Chirwa1, Kristin Dunkle1.
Abstract
Background: Randomised controlled trials (RCTs) are a gold standard for evaluations in public health, economics and social sciences, including prevention of violence against women (VAW). They substantially reduce bias, but do not eliminate measurement error. Control arms often show change, but this is rarely systematically examined.Objective: We present a secondary analysis of data from the control arms of evaluations of VAW prevention programming to understand measurement variance over time, factors that may systematically impact this and make recommendations for stronger trial design and interpretation.Entities:
Keywords: Randomised controlled trials; bias; gender-based violence; non-differential misclassification; proportionate change; regression towards the mean; sample size; violence against women
Mesh:
Year: 2020 PMID: 32338589 PMCID: PMC7241449 DOI: 10.1080/16549716.2020.1748401
Source DB: PubMed Journal: Glob Health Action ISSN: 1654-9880 Impact factor: 2.640
Summary of the methods of the trials
| Evaluation | Study design | Face to face/ | Participants | Control arm sample | Control arm intervention exposure | Papers |
|---|---|---|---|---|---|---|
| Stepping Stones Creating Futures, South Africa | 2-arm RCT: treatment and delayed intervention control. Assessments: baseline, 12 and 24 months | ACASI | Cohort of men and women. Not recruited as couples | Baseline: 336 men, 338 women (17 clusters); Endline: 268 men, 285 women | None | [ |
| Indashyikirwa couples, Rwanda | 2-arm RCT: treatment and control. Assessments: baseline, 12 and 24 months | ACASI | Cohort of men and of women who were married/cohabiting couples | Baseline: 832 women, 830 men; endline: 818 women, 803 men | None | [ |
| Indashyikirwa community, Rwanda | 2-arm RCT: treatment and control. Assessments: baseline and 24 months | Both used (choice provided) | Residents in households in the districts of the study. Repeat cross-sectional data | Baseline and endline: 700 currently-partnered women, 700 men (14 clusters) | None | [ |
| Change Starts at Home, Nepal | 2-arm RCT: treatment and control. Assessments: baseline, 12 and 28 months | F to F | Household residents in the study districts. Repeat cross-sectional data | Baseline: 720 women; Endline: 717 women (18 clusters) | None | [ |
| Women Empowerment Programme, Afghanistan | 2-arm RCT: treatment and delayed intervention control. Assessments: baseline, 12 (data not presented) and 22 months’ | F to F | Cohort of women | Baseline: 714 women (453 currently married); Endline: 537 (441 married) | None | [ |
| Rural Response System, Ghana | 2-arm quasi-experimental study: treatment and control. Assessments: baseline and 24 months | F to F | Households recruitment in 2 control districts. 10 male eas, 10 female. Repeat cross-sectional data | Baseline: 1075 men and 1047 women (20 eas); Endline: 1177 men and 1170 women | None | [ |
| VATU, Zambia | 2-arm RCT: treatment and delayed intervention control. Assessments: baseline and 12 months | ACASI | Cohort of couples (men and women). known problems of IPV and the man harmfully using alcohol | Baseline: 125 couples; endline: 114 women and 108 men | Weekly phone calls (or home visits) by study assessors | [ |
Prevalence of IPV in the control arm across studies, by IPV type, and quantum of change between time points
| Gender | IPV measure | Baseline | 12-mths | 24-mths | Change in percentage points | Largest change in percentage points between two time points | Proportionate change (baseline to endline) | Largest change as a proportion of baseline | |
|---|---|---|---|---|---|---|---|---|---|
| Stepping Stones Creating Futures, South Africa | Women | Physical | 60.1 | 49.3 | 54.4 | −5.7 | −10.8 | −0.095 | −0.180 |
| Sexual | 30.2 | 32.1 | 35.4 | 5.2 | 5.2 | 0.172 | 0.172 | ||
| Severe | 56.2 | 45.1 | 50.9 | −5.3 | −11.1 | −0.094 | −0.198 | ||
| Men | Physical | 50.4 | 53.7 | 44 | −6.4 | −6.4 | −0.127 | −0.127 | |
| Sexual | 30.4 | 44 | 27.2 | −3.2 | 13.6 | −0.105 | 0.447 | ||
| Severe | 46.6 | 49.5 | 40.7 | −5.9 | −5.9 | −0.127 | −0.127 | ||
| Indashyikirwa couples, Rwanda | Women | Physical | 33.1 | 34.4 | 32.2 | −0.9 | 1.3 | −0.027 | −0.027 |
| Sexual | 37.6 | 38.5 | 38.1 | 0.5 | 0.9 | 0.013 | 0.024 | ||
| Severe | 41.1 | 43.5 | 42 | 0.9 | 2.4 | 0.022 | 0.058 | ||
| Men | Physical | 22.8 | 19.4 | 16 | −6.8 | −6.8 | −0.298 | −0.298 | |
| Sexual | 19.6 | 17 | 15.6 | −4 | −4 | −0.204 | −0.204 | ||
| Severe | 22.4 | 19.4 | 16.7 | −5.7 | −5.7 | −0.254 | −0.254 | ||
| Change Starts At Home, Nepal | Women | Physical | 20.4 | 12.9 | 16.0 | −4.4 | −7.5 | −0.216 | −0.368 |
| Sexual | 23.9 | 15.8 | 23.0 | −0.9 | −8.1 | −0.038 | −0.339 | ||
| Severe | 28.4 | 19.6 | 25.8 | −2.6 | −8.8 | −0.092 | −0.310 | ||
| Women’s Empowerment Programme, Afghanistan | Women | Physical | 23.9 | 26.6 | 2.7 | 2.7 | 0.113 | 0.113 | |
| Severe | 16.8 | 19.6 | 2.8 | 2.8 | 0.167 | 0.167 | |||
| RRS, Ghana | Women | Physical | 15.3 | 10.9 | −4.4 | −4.4 | −0.288 | −0.288 | |
| Sexual | 8.5 | 6.8 | −1.7 | −1.7 | −0.200 | −0.200 | |||
| Severe | 17.6 | 11 | −6.6 | −6.6 | −0.375 | −0.375 | |||
| Men | Physical | 10.7 | 12.6 | 1.9 | −1.9 | 0.178 | −0.178 | ||
| Sexual | 16 | 19.8 | 3.8 | 3.8 | 0.238 | 0.238 | |||
| Severe | 17 | 19.4 | 2.4 | 2.4 | 0.141 | 0.141 | |||
| Indashyikirwa community Rwanda | Women | Physical | 40.9 | 41.9 | 1 | 1 | 0.024 | 0.024 | |
| Sexual | 46 | 43.8 | −2.2 | −2.2 | −0.048 | −0.048 | |||
| Severe | 50.9 | 49.7 | −1.2 | −1.2 | −0.024 | −0.024 | |||
| Men | Physical | 22.4 | 24.1 | 1.7 | 1.7 | 0.076 | 0.076 | ||
| Sexual | 16.7 | 17.3 | 0.6 | 0.6 | 0.036 | 0.036 | |||
| Severe | 19.7 | 21.4 | 1.7 | 1.7 | 0.086 | 0.086 | |||
| VATU couples study, Zambia | Women | Physical | 75.2 | 47.4 | −27.8 | −27.8 | −0.37 | −0.37 | |
| Sexual | 69.6 | 46.5 | −23.1 | −23.1 | −0.332 | −0.332 | |||
| Severe | 81.4 | 44.9 | −36.5 | −36.5 | −0.552 | −0.552 | |||
| Men | Physical | 74.4 | 49.4 | −25 | −25 | −0.336 | −0.336 | ||
| Sexual | 43.2 | 38.3 | −5 | −5 | −0.115 | −0.115 | |||
| Severe | 73.7 | 39.0 | −34.7 | −34.7 | −0.529 | −0.529 |
Mean change in the control arms of across studies, all types of IPV and genders
| Mean change in percentage points baseline – endline | Mean largest change in percentage points between two time points | Mean proportionate change (baseline to endline) | Mean largest change as a proportion of baseline | |
|---|---|---|---|---|
| All studies | 7.01 (3.68, 10.33) | 8.39 (5.08, 11.70) | 0.175 | 0.216 |
| All studies with no active control arms | 3.21 (1.59,4.83) | 4.88 (0.94, 8.83) | 0.134 | 0.177 |
| Cohort studies with no active control arms | 4.00 (0.38, 7.62) | 6.29 (0, 17.04) | 0.13 | 0.171 |
| Repeat cross-sectional (5 datasets) | 2.47 (0, 5.56) | 3.57 (0,10.22) | 0.137 | 0.182 |
Change in the control arms of different study types, by type of IPV and gender
| Gender | Change in | Range | Largest change in | Range | Proportionate | Range | Largest change as a proportion of baseline (mean) | Range | |
|---|---|---|---|---|---|---|---|---|---|
| All studies* | Female | 6.70 | 0.9,27.8 | 8.06 | 1.0,27.8 | 0.162 | 0.024,0.37 | 0.201 | 0.024,0.37 |
| Male | 8.36 | 1.7,25.0 | 9.02 | 1.7,25.0 | 0.203 | 0.076, 0.336 | 0.216 | 0.076, 0.336 | |
| All studies with no active controls @ | Female | 3.18 | 0.9, 5.7 | 4.77 | 1,10.8 | 0.127 | 0.024, 0.289 | 0.173 | 0.024, 0.368 |
| Male | 4.20 | 1.7, 6.8 | 5.03 | 1.7,9.7 | 0.17 | 0.077, 0.298 | 0.186 | 0.077,0.298 | |
| Cohorts with no active controls *** | Female | 3.10 | 0.9, 5.7 | 5.23 | 2.2, 10.8 | 0.078 | 0.027, 0.113 | 0.12 | 0.066, 0.180 |
| Male | 6.60 | 6.4, 6.8 | 8.25 | 6.8,9.7 | 0.213 | 0.127, 0.298 | 0.245 | 0.192, 0.298 | |
| Repeat cross-sectional*** | Female | 3.27 | 1, 4.4 | 4.30 | 1.0, 7.5 | 0.176 | 0.024, 0.288 | 0.227 | 0.024, 0.368 |
| Male | 1.80 | 1.7, 1.9 | 1.80 | 1.7, 1.9 | 0.127 | 0.076, 0.178 | 0.127 | 0.076, 0.178 | |
| All studies$ | Female | 5.60 | 0.5, 23.1 | 6.55 | 0.9, 23.1 | 0.134 | 0.013, 0.332 | 0.175 | 0.024, 0.339 |
| Male | 3.32 | 0.6,5.0 | 6.04 | 0.6, 16.8 | 0.14 | 0.036, 0.238 | 0.229 | 0.034, 0.553 | |
| All studies with no active controls ** | Female | 2.10 | 0.5, 5.2 | 3.24 | 0.9, 8.1 | 0.094 | 0.013, 0.172 | 0.144 | 0.024, 0.339 |
| Male | 2.9 | 0.6, 4.0 | 6.3 | 0.6, 16.8 | 0.146 | 0.036, 0.238 | 0.258 | 0.034, 0.553 | |
| Cohorts with no active controls # | Female | 2.85 | 0.5, 5.2 | 2.1 | 0.9, 3.3 | 0.093 | 0.013, 0.172 | 0.067 | 0.024, 0.109 |
| Male | 3.6 | 3.2, 4.0 | 10.4 | 4.0, 16.8 | 0.155 | 0.105, 0.204 | 0.378 | 0.204, 0.553 | |
| Repeat cross-sectional *** | Female | 1.6 | 0.9, 2.2 | 4 | 1.7, 8.1 | 0.095 | 0.038, 0.200 | 0.137 | 0.048, 0.339 |
| Male | 2.2 | 0.6, 3.8 | 2.2 | 0.6, 3.8 | 0.137 | 0.036, 0.238 | 0.196 | 0.036, 0.238 | |
| All studies* | Female | 7.99 | 0.9, 36.5 | 9.91 | 1.2, 36.5 | 0.189 | 0.022, 0.552 | 0.240 | 0.024, 0.552 |
| Male | 10.08 | 1.7, 34.7 | 10.66 | 1.7, 34.7 | 0.228 | 0.086, 0.529 | 0.240 | 0.086, 0.529 | |
| All studies with no active controls ** | Female | 3.23 | 0.9, 6.6 | 5.48 | 1.2, 11.1 | 0.129 | 0.022, 0.167 | 0.189 | 0.024, 0.375 |
| Male | 3.93 | 1.7, 5.9 | 4.65 | 1.7, 8.8 | 0.152 | 0.086, 0.254 | 0.168 | 0.086, 0.254 | |
| Cohorts with no active controls *** | Female | 3 | 0.9, 5.3 | 5.43 | 2.4, 11.1 | 0.094 | 0.022, 0.167 | 0.141 | 0.058, 0.198 |
| Male | 5.8 | 5.7, 5.9 | 7.25 | 5.7, 8.8 | 0.191 | 0.127, 0.254 | 0.222 | 0.189, 0.254 | |
| Repeat cross-sectional*** | Female | 3.47 | 1.2, 6.6 | 5.53 | 1.2, 8.8 | 0.163 | 0.024, 0.375 | 0.236 | 0.024, 0.375 |
| Male | 2.05 | 1.7, 2.4 | 2.05 | 1.7, 2.4 | 0.114 | 0.086, 0.141 | 0.114 | 0.086, 0.141 |
* 12 datasets **9 datasets ***5 datasets $ 11 datasets # 4 datasets @ 10 datasets.